{"id":"https://openalex.org/W2564017374","doi":"https://doi.org/10.1182/blood.v120.21.162.162","title":"Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody","display_name":"Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody","publication_year":2012,"publication_date":"2012-11-16","ids":{"openalex":"https://openalex.org/W2564017374","doi":"https://doi.org/10.1182/blood.v120.21.162.162","mag":"2564017374"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v120.21.162.162","doi":"https://doi.org/10.1182/blood.v120.21.162.162","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.162.162","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083650558","display_name":"Fuliang Chu","orcid":"https://orcid.org/0000-0002-1664-5386","observed_orcids":["https://orcid.org/0000-0002-1664-5386"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fuliang Chu","raw_affiliation_strings":["Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021496101","display_name":"Jason R. Westin","orcid":"https://orcid.org/0000-0002-1824-2337","observed_orcids":["https://orcid.org/0000-0002-1824-2337"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason R. Westin","raw_affiliation_strings":["Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100402941","display_name":"Min Zhang","orcid":"https://orcid.org/0000-0002-7213-0918","observed_orcids":["https://orcid.org/0000-0002-7213-0918"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Min Zhang","raw_affiliation_strings":["Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060924118","display_name":"Lei Feng","orcid":"https://orcid.org/0000-0002-4414-9910","observed_orcids":["https://orcid.org/0000-0002-4414-9910"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lei Feng","raw_affiliation_strings":["University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024470416","display_name":"Veerabhadran Baladandayuthapani","orcid":"https://orcid.org/0000-0001-9107-3157","observed_orcids":["https://orcid.org/0000-0001-9107-3157"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Veerabhadran Baladandayuthapani","raw_affiliation_strings":["Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115695030","display_name":"Zhiqiang Wang","orcid":"https://orcid.org/0000-0002-4037-3130","observed_orcids":["https://orcid.org/0000-0002-4037-3130"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Zhiqiang Wang","raw_affiliation_strings":["Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109337471","display_name":"Rochelle Allen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rochelle Allen","raw_affiliation_strings":["Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Wallace","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael Wallace","raw_affiliation_strings":["Diagnostic Radiology, The University of Texas MD Anderson Cancer Center,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diagnostic Radiology, The University of Texas MD Anderson Cancer Center,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034269049","display_name":"Luis M. Vence","orcid":"https://orcid.org/0000-0003-3441-4095","observed_orcids":["https://orcid.org/0000-0003-3441-4095"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Luis Vence","raw_affiliation_strings":["Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060265796","display_name":"Laszlo George Radvanyi","orcid":"https://orcid.org/0000-0003-1603-3547","observed_orcids":["https://orcid.org/0000-0003-1603-3547"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Laszlo Radvanyi","raw_affiliation_strings":["Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Hoston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Hoston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074743570","display_name":"Larry W. Kwak","orcid":"https://orcid.org/0000-0002-1884-5349","observed_orcids":["https://orcid.org/0000-0002-1884-5349"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry W. Kwak","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045699031","display_name":"Rinat Rotem\u2010Yehudar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092199","display_name":"CureTech (Israel)","ror":"https://ror.org/01cd7k542","country_code":"IL","type":"company","lineage":["https://openalex.org/I4210092199"]}],"countries":["IL"],"is_corresponding":true,"raw_author_name":"Rinat Rotem-Yehudar","raw_affiliation_strings":["CureTech, Ltd., Israel,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CureTech, Ltd., Israel,","institution_ids":["https://openalex.org/I4210092199"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111422728","display_name":"R. Eric Davis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"R Eric Davis","raw_affiliation_strings":["Lymphoma and Myeloma, University of Texas, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma and Myeloma, University of Texas, Houston, TX, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064752432","display_name":"Sattva Swarup Neelapu","orcid":"https://orcid.org/0000-0003-1045-4914","observed_orcids":["https://orcid.org/0000-0003-1045-4914"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sattva S. Neelapu","raw_affiliation_strings":["Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5024470416","https://openalex.org/A5034269049","https://openalex.org/A5045699031","https://openalex.org/A5060265796","https://openalex.org/A5060924118","https://openalex.org/A5100402941","https://openalex.org/A5109337471","https://openalex.org/A5111422728","https://openalex.org/A5115695030"],"corresponding_institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210092199"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.35890443,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"120","issue":"21","first_page":"162","last_page":"162"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.005499999970197678,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-follicular-lymphoma","display_name":"relapsed follicular lymphoma","score":0.8999999761581421},{"id":"https://openalex.org/keywords/anti-pd-1-monoclonal-antibody","display_name":"anti-PD-1 monoclonal antibody","score":0.9750000238418579},{"id":"https://openalex.org/keywords/tumor-infiltrating-immune-cells","display_name":"tumor-infiltrating immune cells","score":0.7239999771118164},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.8550000190734863},{"id":"https://openalex.org/keywords/gene-expression-signatures","display_name":"gene expression signatures","score":0.48500001430511475},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.6830000281333923},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.5479999780654907},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.7099999785423279},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.8190000057220459},{"id":"https://openalex.org/keywords/rituximab-combination","display_name":"rituximab combination","score":0.6690000295639038}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7457742691040039},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.6553120613098145},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.568827748298645},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5355021953582764},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5153743624687195},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.5080916881561279},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5037311911582947},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.43936675786972046},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3524496555328369},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.34671106934547424},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.33475083112716675},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14771223068237305},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.08201190829277039},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v120.21.162.162","doi":"https://doi.org/10.1182/blood.v120.21.162.162","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.162.162","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8500000238418579,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2062566755","https://openalex.org/W2084396664","https://openalex.org/W1994176969","https://openalex.org/W2761932222","https://openalex.org/W2028043880","https://openalex.org/W2094454764","https://openalex.org/W2094591637","https://openalex.org/W2488602574","https://openalex.org/W2944081921","https://openalex.org/W2113605807"],"abstract_inverted_index":{"Abstract":[0,1],"162":[2],"Background:":[3],"The":[4,473],"coinhibitory":[5],"receptor":[6,318],"programmed":[7],"death":[8],"(PD)-1":[9],"is":[10,26],"markedly":[11],"increased":[12,674],"on":[13,90,108,137,176,209,320,497,549,588,591],"peripheral":[14],"blood":[15],"(PB)":[16],"and":[17,25,44,51,64,68,76,97,113,131,163,175,237,255,295,302,343,370,485,513,524,542,565,640,646,652,658,688,710],"intratumoral":[18],"T":[19,50,288,292,305,329,356,427,438,445,461,470,551,644,651],"cells":[20,92,119,187,274,289,293,306,322,330,428,439,446,462,471,552,645,654],"in":[21,70,94,234,239,267,275,312,359,398,425,443,531,553,605,633,648,655,662,728],"follicular":[22,436],"lymphoma":[23],"(FL)":[24],"associated":[27,354,630],"with":[28,73,147,280,355,388,447,479,503,529,602,614,631,672,680,723],"impaired":[29],"T-cell":[30],"function.":[31],"CT-011":[32,67,89,123,158,559,592,627,693,709],"(pidilizumab),":[33],"a":[34,56,243,264,404,712],"humanized":[35],"anti":[36],"PD-1":[37,453],"monoclonal":[38],"antibody,":[39],"blocks":[40],"the":[41,46,62,77,86,95,141,180,260,268,313,316,518,538,562,582,585,634,656,659,704],"PD-1/PD-ligand":[42],"pathway":[43],"enhances":[45,537,561],"function":[47,539,695],"of":[48,66,88,104,116,144,157,183,229,247,271,315,335,351,375,407,452,507,540,568,572,578,584,609,626,636,650,667,676,685,696,706,708,717,726],"antitumor":[49,677],"NK":[52,321,653],"cells.":[53],"We":[54,100,262,308,372,402],"conducted":[55],"phase":[57],"II":[58],"trial":[59],"to":[60,174,195,382,421,434,457],"determine":[61,196],"safety":[63],"efficacy":[65,219],"rituximab":[69,132],"patients":[71],"(pts)":[72],"relapsed":[74],"FL":[75,610],"clinical":[78,105,389,721],"results":[79,556,700],"are":[80],"reported":[81,411],"separately.":[82],"Here,":[83],"we":[84,594],"evaluated":[85],"effects":[87,567],"immune":[91,110,118,198,273],"both":[93,571],"PB":[96,109,162,185,272,657],"tumor":[98,377,399,526,660],"microenvironment.":[99],"also":[101,309,487],"determined":[102],"predictors":[103],"outcome":[106,589],"based":[107,496],"cell":[111,199,357,574],"subsets":[112],"molecular":[114],"features":[115],"tumor-infiltrating":[117],"at":[120],"baseline.":[121],"Methods:":[122],"was":[124,207,232,252,256,486,629,683],"given":[125],"every":[126,159],"4":[127,130,135,160,240],"wks":[128],"\u00d7":[129,134],"weekly":[133],"starting":[136],"day":[138,177,276,344,360],"17":[139],"after":[140,179],"first":[142,181],"infusion":[143,182],"CT-011.":[145,184],"Pts":[146],"response":[148,225,687],"or":[149,449,465,468,570],"stable":[150],"disease":[151],"received":[152],"8":[153],"additional":[154],"optional":[155],"infusions":[156],"wks.":[161],"core":[164,210,338],"needle":[165,211,339],"biopsies":[166,340,378],"from":[167,337,379],"involved":[168],"lymph":[169],"nodes":[170],"were":[171,189,331],"collected":[172],"prior":[173],"14":[178,248,277,345,361],"mononuclear":[186],"(PBMC)":[188],"analyzed":[190,373],"by":[191,393,412,481,491,501],"multiparametric":[192],"flow":[193],"cytometry":[194],"various":[197],"subsets.":[200],"Whole":[201],"genome":[202],"gene":[203,384,475,492,669],"expression":[204,314,506,666],"profiling":[205],"(GEP)":[206],"performed":[208],"biopsies.":[212],"Results:":[213],"Of":[214],"29":[215],"pts":[216,381,611,718],"eligible":[217],"for":[218,226,259,431,715,719],"analysis,":[220],"19":[221],"had":[222],"an":[223,227,606],"objective":[224],"ORR":[228],"66%.":[230],"CR":[231],"observed":[233,263,310],"15":[235],"(52%)":[236],"PR":[238],"(14%).":[241],"After":[242],"median":[244,250],"follow":[245],"up":[246,349],"mo,":[249,254],"PFS":[251,394,480,522,690],"21.1":[253],"not":[257,600],"reached":[258],"responders.":[261],"significant":[265,488],"increase":[266,311,632],"absolute":[269],"number":[270],"samples":[278,362],"compared":[279,679],"baseline":[281,376],"including":[282,363],"total":[283],"lymphocyte":[284],"count":[285],"(p<0.01),":[286,294],"CD3+":[287],"(p=0.01),":[290,298],"CD4+":[291,296,426,444,643],"naive":[297],"effector":[299,460,467,638],"memory":[300,304,642],"(p=0.02),":[301],"central":[303,641],"(p<0.05).":[307],"activating":[317],"NKG2D":[319],"(p=0.01).":[323],"In":[324,576],"contrast,":[325],"CD8+":[326],"terminally":[327],"differentiated":[328],"decreased":[332],"(p=0.02).":[333],"Comparison":[334],"GEP":[336,374],"obtained":[341],"pretreatment":[342],"(n=8":[346],"pairs)":[347],"showed":[348],"regulation":[350],"several":[352],"genes":[353,409,500],"activation":[358,649],"CD58,":[364],"CTLA4,":[365],"NFATC1,":[366],"CCR5,":[367],"PBK,":[368],"TSLP,":[369],"ZBTB32.":[371],"18":[380],"find":[383],"signatures":[385],"that":[386,534,558,581,596,692],"correlated":[387,477],"outcome,":[390],"as":[391],"measured":[392],"and/or":[395],"quantitative":[396],"change":[397],"size":[400],"(%change).":[401],"tested":[403],"\u201cPD-1hi_Down\u201d":[405],"signature":[406,476,587,598],"41":[408],"previously":[410],"us":[413],"(Chu":[414],"et":[415,618],"al,":[416],"Blood,":[417],"Nov":[418],"2011;":[419],"118:2648)":[420],"be":[422,435,458],"less":[423,525],"expressed":[424],"strongly":[429],"positive":[430],"PD-1,":[432],"likely":[433,456],"helper":[437],"(Tfh,":[440],"PD-1hi),":[441],"than":[442],"intermediate":[448],"low":[450],"levels":[451],"surface":[454],"staining,":[455],"exhausted":[459,697],"(Teffs,":[463],"PD-1int)":[464],"activated":[466],"nai\u0308ve":[469],"(PD-1lo).":[472],"PD-1hi_Down":[474,586,668],"significantly":[478],"univariate":[482],"Cox":[483],"regression":[484],"when":[489],"examined":[490],"set":[493],"enrichment":[494],"analysis":[495],"ranking":[498],"all":[499],"correlation":[502],"%change.":[504],"Low":[505],"this":[508,597,724],"signature,":[509,670],"suggesting":[510,691],"more":[511],"Tfh":[512,541,682],"fewer":[514],"PD-1+":[515,543],"Teffs":[516,544,678],"within":[517],"tumor,":[519],"predicted":[520],"shorter":[521],"duration":[523],"shrinkage.":[527],"Combined":[528],"our":[530,579],"vitro":[532],"findings":[533],"anti-PD-1":[535],"Ab":[536],"but":[545],"has":[546],"no":[547],"effect":[548,583],"PD-1lo":[550],"FL,":[554],"these":[555,573],"suggest":[557],"therapy":[560],"respective":[563],"pro-":[564],"anti-tumor":[566],"one":[569],"types.":[575],"support":[577],"conclusion":[580],"depends":[590],"therapy,":[593],"found":[595],"did":[599],"correlate":[601],"overall":[603],"survival":[604],"external":[607],"dataset":[608],"treated":[612],"largely":[613],"chemotherapy":[615],"alone":[616],"(Dave":[617],"al.,":[619],"NEJM":[620],"2004;":[621],"351:":[622],"2109).":[623],"Conclusions:":[624],"Administration":[625],"(pidilizumab)":[628],"numbers":[635,675],"nai\u0308ve,":[637],"memory,":[639],"resulted":[647],"microenvironment":[661],"FL.":[663,729],"A":[664],"high":[665],"consistent":[671],"relatively":[673],"protumor":[681],"predictive":[684,713],"good":[686],"improved":[689],"restores":[694],"Teffs.":[698],"These":[699],"provide":[701],"insight":[702],"into":[703],"mechanism":[705],"action":[707],"offer":[711],"biomarker":[714],"selection":[716],"future":[720],"trials":[722],"class":[725],"agents":[727],"Disclosures:":[730],"Rotem-Yehudar:":[731],"CureTech":[732],"Ltd:":[733],"Employment,":[734],"Research":[735,740],"Funding.":[736,741],"Neelapu:Cure":[737],"Tech,":[738],"Ltd.:":[739]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}